25.55
Schlusskurs vom Vortag:
$26.11
Offen:
$25.851
24-Stunden-Volumen:
10,159
Relative Volume:
0.25
Marktkapitalisierung:
$301.52M
Einnahmen:
$9.71M
Nettoeinkommen (Verlust:
$-29.96M
KGV:
-7.342
EPS:
-3.48
Netto-Cashflow:
$-14.79M
1W Leistung:
-3.98%
1M Leistung:
-0.47%
6M Leistung:
+10.61%
1J Leistung:
+25.68%
Xoma Royalty Corp Stock (XOMA) Company Profile
Firmenname
Xoma Royalty Corp
Sektor
Branche
Telefon
510-204-7239
Adresse
2200 POWELL STREET, EMERYVILLE, CA
Vergleichen Sie XOMA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
XOMA
Xoma Royalty Corp
|
25.55 | 301.52M | 9.71M | -29.96M | -14.79M | -3.48 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
2021-09-07 | Herabstufung | Wedbush | Outperform → Neutral |
2021-06-29 | Eingeleitet | Aegis Capital | Buy |
2021-01-19 | Bestätigt | H.C. Wainwright | Buy |
2018-01-18 | Bestätigt | H.C. Wainwright | Buy |
2017-10-17 | Fortgesetzt | H.C. Wainwright | Buy |
2017-09-05 | Hochstufung | Wedbush | Neutral → Outperform |
2017-06-12 | Eingeleitet | H.C. Wainwright | Buy |
2016-11-14 | Herabstufung | Wedbush | Outperform → Neutral |
2016-03-11 | Bestätigt | Wedbush | Outperform |
2015-07-23 | Herabstufung | Jefferies | Buy → Hold |
2015-07-22 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
2015-07-22 | Herabstufung | Piper Jaffray | Overweight → Neutral |
2014-10-10 | Fortgesetzt | ROTH Capital | Buy |
2014-04-29 | Hochstufung | MLV & Co | Hold → Buy |
2014-03-11 | Herabstufung | MLV & Co | Buy → Hold |
2014-03-05 | Bestätigt | Ladenburg Thalmann | Buy |
2013-10-31 | Bestätigt | MLV & Co | Buy |
2013-05-09 | Bestätigt | Ladenburg Thalmann | Buy |
2012-05-14 | Eingeleitet | Cowen & Co | Outperform |
2011-03-31 | Bestätigt | MLV Capital | Buy |
2011-03-23 | Bestätigt | RBC Capital Mkts | Outperform |
2011-01-06 | Bestätigt | Ladenburg Thalmann | Buy |
2011-01-04 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Xoma Royalty Corp Aktie (XOMA) Neueste Nachrichten
XOMA (NASDAQ:XOMA) Cut to Sell at StockNews.com - MarketBeat
HC Wainwright Issues Pessimistic Forecast for XOMA (NASDAQ:XOMA) Stock Price - MarketBeat
XOMA stock price target cut to $104 by H.C. Wainwright - MSN
HC Wainwright Has Lowered Expectations for XOMA (NASDAQ:XOMA) Stock Price - Defense World
StockNews.com Downgrades XOMA (NASDAQ:XOMA) to Sell - Defense World
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Exclusive Healthcare Insights: XOMA Leadership Takes Center Stage at Oppenheimer Conference - StockTitan
XOMA (NASDAQ:XOMAP) Trading Up 0.4% – Should You Buy? - Defense World
Forecasting The Future: 5 Analyst Projections For XOMA Royalty - Benzinga
XOMA Co. (NASDAQ:XOMA) Major Shareholder Bvf Partners L. P/Il Sells 500,742 Shares - MarketBeat
Short Interest in XOMA Co. (NASDAQ:XOMAO) Decreases By 34.2% - Defense World
Xoma royalty corp sees sale of $16.98 million in stock by investors - MSN
BIOTECHNOLOGY VALUE FUND L P Reduces Stake in XOMA Royalty Corp - GuruFocus.com
Xoma royalty corp sees sale of $16.98 million in stock by investors By Investing.com - Investing.com India
Barclays PLC Has $298,000 Stake in XOMA Co. (NASDAQ:XOMA) - Defense World
XOMA (NASDAQ:XOMA) Upgraded at StockNews.com - MarketBeat
XOMA (NASDAQ:XOMA) Stock Rating Upgraded by StockNews.com - Defense World
XOMA Royalty Corporation: High-Risk Royalty Aggregator Best Avoided - Seeking Alpha
XOMA (NASDAQ:XOMA) and Oragenics (NYSE:OGEN) Head to Head Review - Defense World
Xoma Royalty's chief investment officer buys $13,974 in stock By Investing.com - Investing.com Australia
XOMA (NASDAQ:XOMAP) Trading Down 0.8% – Here’s Why - Defense World
XOMA (NASDAQ:XOMA) Earns “Buy” Rating from HC Wainwright - Defense World
XOMA shares gain momentum, analyst notes 10%+ revenue growth potential from RZ358 - Investing.com
XOMA (NASDAQ:XOMA) Downgraded by StockNews.com to Sell - MarketBeat
HC Wainwright Reiterates "Buy" Rating for XOMA (NASDAQ:XOMA) - MarketBeat
Barclays PLC Acquires 8,447 Shares of XOMA Co. (NASDAQ:XOMA) - Defense World
Geode Capital Management LLC Purchases 1,138 Shares of XOMA Co. (NASDAQ:XOMA) - Defense World
State Street Corp Has $3.78 Million Holdings in XOMA Co. (NASDAQ:XOMA) - Defense World
Short Interest in XOMA Co. (NASDAQ:XOMAO) Grows By 26.7% - Defense World
XOMA Co. (NASDAQ:XOMA) Sees Significant Growth in Short Interest - Defense World
XOMA (NASDAQ:XOMA) Lowered to “Sell” Rating by StockNews.com - Defense World
XOMA (NASDAQ:XOMA) Lowered to "Sell" Rating by StockNews.com - MarketBeat
BNP Paribas Financial Markets Purchases 795 Shares of XOMA Co. (NASDAQ:XOMA) - Defense World
XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends for Series A and B Shares - StockTitan
XOMA (NASDAQ:XOMA) Earns Buy Rating from HC Wainwright - Defense World
XOMA (NASDAQ:XOMAP) Trading Down 0.6% – Should You Sell? - Defense World
XOMA (NASDAQ:XOMA) Receives Buy Rating from HC Wainwright - MarketBeat
XOMA Co. (NASDAQ:XOMAO) Sees Significant Increase in Short Interest - Defense World
XOMA Co. (NASDAQ:XOMA) Shares Sold by Fmr LLC - MarketBeat
A Glimpse Into The Expert Outlook On XOMA Royalty Through 4 Analysts - Benzinga
XOMA shares target boosted, retains buy on new acquisition By Investing.com - Investing.com South Africa
XOMA Royalty’s Pulmokine brings seralutinib to pipeline - The Pharma Letter
XOMA shares target boosted, retains buy on new acquisition - Investing.com
Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M - Endpoints News
Xoma Royalty acquires Pulmokine for $20M - TipRanks
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in - The Bakersfield Californian
Finanzdaten der Xoma Royalty Corp-Aktie (XOMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xoma Royalty Corp-Aktie (XOMA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
BVF PARTNERS L P/IL | 10% Owner |
Jan 24 '25 |
Sale |
26.10 |
149,975 |
3,914,348 |
0 |
Sitko Bradley | Chief Investment Officer |
Jan 08 '25 |
Buy |
25.60 |
313 |
8,013 |
313 |
Sitko Bradley | Chief Investment Officer |
Jan 08 '25 |
Buy |
25.70 |
232 |
5,962 |
82 |
Sitko Bradley | Chief Investment Officer |
Dec 31 '24 |
Buy |
25.90 |
300 |
7,770 |
9,150 |
BURNS THOMAS M. | SVP, Finance & CFO |
Nov 11 '24 |
Option Exercise |
0.00 |
17,773 |
0 |
24,328 |
BURNS THOMAS M. | SVP, Finance & CFO |
Nov 13 '24 |
Sale |
29.94 |
9,775 |
292,664 |
14,553 |
Hughes Owen | Chief Executive Officer |
Nov 11 '24 |
Option Exercise |
0.00 |
53,360 |
0 |
56,860 |
Hughes Owen | Chief Executive Officer |
Nov 13 '24 |
Sale |
29.95 |
21,881 |
655,336 |
34,979 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):